HRD + BRCA2 mutation	Ovarian Cancer	HRD + BRCA2 mutation	Ovarian Cancer	bevacizumab + olaparib Sensitive: A2 - Guideline bevacizumab + olaparib Sensitive : A2	bevacizumab + olaparib Sensitive: A2 - Guideline bevacizumab + olaparib Sensitive : A2
HRD + BRCA2 mutation	Fallopian Tube Cancer	HRD + BRCA2 mutation	Fallopian Tube Cancer	bevacizumab + olaparib Sensitive: A2 - Guideline bevacizumab + olaparib Sensitive : A2	bevacizumab + olaparib Sensitive: A2 - Guideline bevacizumab + olaparib Sensitive : A2
HRD + BRCA2 mutation	Peritoneal Cancer	HRD + BRCA2 mutation	Peritoneal Cancer	bevacizumab + olaparib Sensitive: A2 - Guideline bevacizumab + olaparib Sensitive : A2	bevacizumab + olaparib Sensitive: A2 - Guideline bevacizumab + olaparib Sensitive : A2
HRD + BRCA2 mutation	Ovarian Cancer	HRD + BRCA2 mutation	Ovarian Cancer	niraparib Sensitive: C3 – Early Trials niraparib Sensitive : C3	niraparib Sensitive: C3 – Early Trials niraparib Sensitive : C3
HRD + BRCA2 mutation	Fallopian Tube Cancer	HRD + BRCA2 mutation	Fallopian Tube Cancer	niraparib Sensitive: C3 – Early Trials niraparib Sensitive : C3	niraparib Sensitive: C3 – Early Trials niraparib Sensitive : C3
HRD + BRCA2 mutation	Peritoneal Cancer	HRD + BRCA2 mutation	Peritoneal Cancer	niraparib Sensitive: C3 – Early Trials niraparib Sensitive : C3	niraparib Sensitive: C3 – Early Trials niraparib Sensitive : C3
HRD + BRCA2 mutation	Endometrial Cancer	HRD + BRCA2 mutation	Endometrial Cancer	niraparib Sensitive: C3 – Early Trials niraparib Sensitive : C3	niraparib Sensitive: C3 – Early Trials niraparib Sensitive : C3

HRD + BRCA2 mutation

Associations